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The  effect  of rutin  on  memory  was  evaluated  in  rats  injected  with  A.
Rutin  increased  ERK1,  CREB  and  BDNF  gene  expression  in  the  hippocampus.
Rutin  increased  memory  retrieval  in passive  avoidance  task.
Rutin  decreased  oxidative  stress  of A  on memory.
Rutin  potentially  ameliorates  the destructive  effects  of A  on  memory.
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a  b  s  t  r  a  c  t
Flavonoids  are  present  in  foods  such  as  fruits  and  vegetables.  A  relationship  between  the  consumption  of
ﬂavonoid-rich  foods  and  prevention  of human  disease  including  neurodegenerative  disorders  has  been
demonstrated.  We  assessed  the effect  of rutin  (3,3′,4′,5,7-pentahydroxyﬂavone-3-rhamnoglucoside)  on
the  mitogen-activated  protein  kinase  (MAPK)  pathway,  memory  retrieval  and  oxidative  stress  in rats
injected  with  -amyloid  (A), which  is implicated  to  have  an  important  role  in  Alzheimer’s  disease  (AD).
A  was  injected  bilaterally  in the  deep  frontal  cortex  of  rat  brain.  Next,  rutin  and  saline  were  injected




regulated  protein  kinase  1  (ERK1),  cAMP  response  element-binding  protein  (CREB)  and  brain-derived
neurotrophic  factor (BDNF)  gene  expression  in the  hippocampus  of  rats. Rutin  (100  mg/kg)  signiﬁcantly
increased  memory  retrieval  compared  to  the  control  group.  Malondialdehyde  (MDA)  level  in  the  hip-
pocampus  of  the  rutin  group  was  signiﬁcantly  lower  than  those  in the control  group.  The  content  of
sulfhydryl  groups  in the  rutin  group  was  higher  than  that  in the  control  group.  The  ﬁndings  show  a
possibility  that  rutin may  have  beneﬁcial  effects  against  neurotoxicity  of  A  on  memory  in  rats.Abbreviations: A, -amyloid; AD, Alzheimer’s disease; Akt/PKB, protein kinase B; A
otrophic factor; CAT, catalase; CREB, cAMP response element-binding protein; GSH, 
rotein kinase; JNK, c-Jun N-terminal kinase; i.p., interaperitoneally; MAP  kinase, mito
itogen activated kinase kinase; MDA, malondialdehyde; mTor, mammalian target of rap
entylenetetrazole; SH, sulfhydryl; SOD, superoxide dismutase; TrkB, tropomyosin recep
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rc, activity-regulated cytoskeleton-associated protein; BDNF, brain-derived neu-
glutathione; GPx, glutathione peroxidase; ERK1/2, extracellular signal-regulated
gen-activated protein kinase; MCAO, middle cerebral artery occlusion; MEK1/2,
amycin; PBS, phosphate buffered saline; PI3K, phosphatidyl inositiol 3-kinase; PTZ,
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of  ketamine/xylazine (60 mg/kg and 6 mg/kg, respectively). Animals were sacriﬁcedS. Moghbelinejad et al. / Toxic
. Introduction
Alzheimer disease (AD) is the most common cause of demen-
ia. Its prevalence ranges from 3% to almost 50% between the ages
f 65–85 years (Simon et al., 2009). In recent years, ﬂavonoid
erivatives have been proposed to be useful in the treatment of
eurodegenerative disorders such as AD (Vauzour et al., 2008; Patel
t al., 2008). Flavonoids such as puerarin, baicalein and kaempferol
ave been reported to be protective against A peptide neuro-
oxicity in in vitro and in vivo studies (Kim et al., 2010; Lu et al.,
011; Zhang et al., 2008). Flavonoids are polyphenolic compounds
ound in food plants, and are divided into the following six groups:
avonols, ﬂavones, isoﬂavone, ﬂavanones, ﬂavanols and antho-
yanidins (Spencer, 2008).
Rutin (quercetin-3-O-rutinoside) is a ﬂavonol found in plants
uch as buckwheat, passion ﬂower, apple and tea (Gulpinar
t al., 2012; Kuntic´  et al., 2007). Rutin has been found to
ave several neuropharmacological effects including anticonvul-
ant, antidepressant and neuroprotective effects on the central
ervous system (Khan et al., 2009; Machado et al., 2008;
assiri-Asl et al., 2008; Tongjaroenbuangam et al., 2011; Yang
t al., 2012). Several studies have also focused on the effects
f rutin on cognition and memory in different models of
emory impairment in different animals (Gupta et al., 2003;
u et al., 2007; Pyrzanowska et al., 2012; Richetti et al.,
011).
Previously, we have found that rutin has a potential role in
nhancing memory retrieval. We  observed that 1 week of daily
dministration of rutin (10 mg/kg) prior to training resulted in
ncreased retrieval of memory in the ﬁrst, second and third reten-
ion tests of passive avoidance test in normal rats (Nassiri-Asl
t al., 2010). Furthermore, pretreatment with rutin (50–100 mg/kg)
efore administration of pentylenetetrazole (PTZ) every other
ay prior to training signiﬁcantly decreased the severity of
eizures and resulted in increased retrieval of memory in kin-
led rats during the ﬁrst and second retention tests of the
assive avoidance task (Nassiri-Asl et al., 2010). Recently, it was
eported that rutin supplementation was effective in suppress-
ng memory dysfunction caused by streptozotocin in rats. It
educed inﬂammation and prevented the morphological changes
nduced by streptozotocin in the hippocampus (Javed et al.,
012).
The mitogen-activated protein kinase (MAPK) cascade that
ncludes extracellular signal-regulated protein kinase (ERK1/2) and
AMP response element-binding protein (CREB) is involved in neu-
al survival and plasticity. It has been shown that activation of
his cascade causes long lasting changes in synaptic plasticity and
emory (Spencer, 2008). BDNF is a neurotrophin that affects the
urvival and function of neurons in the central nervous system and
s important for appropriate synaptic connection formation during
evelopment and for learning and memory in adults (Thomas and
avies, 2005).
It has been suggested that the A, the major protein
omponent of senile plaque, plays an important role in patho-
enesis of AD. The A-related fragments (A (1–40), A (1–42))
xhibit toxicity to neurons (Shin et al., 1997; Wang et al.,
001). A aggregation could contribute to memory impair-
ent especially through inducing transcripts of the genes
nvolved in inﬂammatory or apoptotic pathways (Hemmati et al.,
013).
Thus, in this study, we focused on the possible effects of rutin
n MAPK and BDNF gene expression and memory retrieval in
-amyloid-injected rats. Furthermore, malondialdehyde (MDA)
nd sulfhydryl (SH) groups were measured as indicators of
ipid peroxidation and oxidative stress in this model of memory
mpairment.Letters 224 (2014) 108– 113 109
2. Materials and methods
2.1. Animals
Male Wistar rats (200–250 g) were obtained from the Razi Institute (Karaj, Iran)
and  housed in groups of four per cage under standard laboratory conditions. Rats
were housed in a room maintained at a constant room temperature (21 ± 2 ◦C) under
a  12L:12D cycle with free access to food and water. All animal experiments were
performed in accordance with the European Communities Council Directive of 24
November 1986 (86/609/EEC) to minimize the number of animals used and their
suffering.
2.2. Chemicals
Rutin, -amyloid (A) (1–42) and phosphate buffered saline (PBS) were
purchased from Sigma (Sigma–Aldrich, St. Louis, MO,  USA). Other drugs used
in  this study included xylazine (Loughrea, Co. Galway, Ireland) and ketamine
(Rotexmedica, GmbH, Germany). 2,2′-Dinitro-5,5′-dithiodibenzoic acid (DTNB), 2-
thiobarbituric acid (TBA), Tris (Trizma® base), sodium ethylenediaminetetraacetic
acid (Na EDTA), methanol, trichloroacetic acid (TCA), potassium chloride (KCl) and
hydrochloric acid (HCl) were purchased from Merck (Darmstadt, Germany). Rutin
daily dissolved in saline at concentration 220 mg/5 ml  and was injected i.p. to ani-
mals.
2.3. Preparation of A  ˇ and surgery
A (1–42) fragments were prepared as stock solutions in sterile 0.1 M PBS (pH
7.4) and aliquoted and stored at −80 ◦C until use (van der Stelt et al., 2006). After
defrosting the aliquots, 3 l of A solution (30 ng) was  used for each injection.
2.4. Surgery and experimental procedures
The rats were anaesthetized with ketamine (60 mg/kg, i.p.) and xylazine
(6  mg/kg, i.p.) and placed in a stereotaxic apparatus (Stoelting, Wood Dale, IL,
USA). A was  bilaterally injected into the animal’s frontal cortex (Hemmati et al.,
2013) as follows: anterior–posterior (AP), 3.2 mm from the bregma; medial–lateral
(ML), 2 mm from the midline and dorsal–ventral (DV), 3 mm from the skull surface
(Paxinos and Watson, 1998).
For administration of A, animals were gently hand-restrained and drug
infusions were made using an injection needle (24-gauge) connected through a
polyethylene tube to a 5 l Hamilton syringe (infusion rate 1 ml/min). The nee-
dles were left in place for 1 min  following the microinjections to minimize the
ﬂow  of drug solution up the track (Nassiri-Asl et al., 2008). Rats were divided into
two groups of 30 animals each. A was injected bilaterally (3 l = 30 ng each side)
in the deep frontal cortex of the rat brain. In the control group, saline (10 ml/kg,
i.p.) was injected after administration of A, every day for 3 weeks. In second
group, rutin (100 mg/kg, i.p.) was injected after administration of A, every day for
3  weeks.
2.5. Passive avoidance apparatus
After 3 weeks of injection of A and treatment of animals with saline and rutin,
the passive avoidance task was  conducted in animals. All rats were allowed to habit-
uate, and the acquisition trial was performed 30 min  after the habituation trial. Then,
each rat was  gently placed in the light compartment of the apparatus. After 5 s, the
guillotine door was  opened and the rat was allowed to enter the dark compart-
ment. The latency with which each rat crossed into the dark compartment was
recorded. The rats that waited more than 100 s to cross into the dark compart-
ment were eliminated from the experiments. Once the rat crossed with all four
paws into the next compartment, the guillotine door was closed and the rat was
returned to its home cage. The acquisition trial was performed 30 min  after the
habituation trial. The rat was placed in the light compartment, and the guillotine
door was opened 5 s later. As soon as the rat crossed into the dark compartment,
the  door was closed and a foot shock (0.5 mA  intensity, 3 s) was immediately deliv-
ered to the grid ﬂoor of the dark room by an insulated stimulator (Nassiri-Asl et al.,
2012).
One day after training, retention tests were conducted to evaluate memory per-
formance. Each rat was placed in the light compartment for 20 s, the door was
opened, and the step-through latency for entering into the dark compartment was
measured. The test session ended when the rat entered the dark compartment or
remained in the light compartment for 300 s. No electric shock was applied during
these sessions (Nassiri-Asl et al., 2012).
At  the end of the behavioral studies, rats were anaesthetized with i.p. injectionunder anesthesia. Then, whole hippocampal tissues were dissected and quickly
removed and cleaned with chilled saline. One hippocampus of each brain was
used  for biochemical analysis and the other hippocampus was snap frozen and
kept at −80 ◦C to be later used for gene expression analysis (Hemmati et al.,
2013).
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Table 1





BDNF F: CGGCTTGGAGAAGGAAAC 71
R: GAACCCGGTCTCATCAAAG
ERK1 F: GTTCTGGAATGGAAGGGCTA 91
R: GGATGAGTAGGGCAGAGCTT
ERK2 F: CAGTTCTTGACCCTGGTCCT 68
R: AACGGCTCAAAGGAGTCAAG
CREB1 F: TACAGGGCCTGCAGACATTA 112
R: TTGCTGGGCACTAGAATCTG














































Fig. 1. The effects of 100 mg/kg rutin on the acquisition and retention tests in
expression
Rutin signiﬁcantly increased ERK1, CREB and BDNF gene expres-
sion in the hippocampi of rats compared to controls (t(20) = 2.52,R: AACAGTCCGCCTAGAAGCAT
.6. Real-time PCR and comparative threshold cycle method
Then, frozen whole hippocampus tissues were homogenated using an Ultrasonic
rocessor UP100H (Hielsher, Germany). Total RNA was extracted using the total
NA extraction kit (Jena Bioscience, GmbH, Jena, Germany). Next, RNA was  reverse
ranscribed using the Revert Aid First Strand cDNA Synthesis Kit (Thermo Scientiﬁc
ermentas, Waltham, MA,  USA).
Quantitative RT-PCR was  used to detect BDNF, ERK1, ERK2 and CREB1 RNA
ontent in hippocampal tissues. The target and -actin (internal control) genes
ere ampliﬁed with appropriate primers (Table 1). All primers were designed
sing Gene Runner software (version 3.05). SYBR Green I real-time PCR assay was
erformed in ﬁnal reaction volumes of 20 l with 10 l of SYBR Green I Mas-
er Mix (Bioneer, Korea), 10 pmol of forward and reverse primers and 20 ng total
NA-derived cDNAs. Thermal cycling was performed using the ABI-7500 (Applied
iosystems, Foster, CA, USA) Sequence Detection System using the following cycling
ondition: 10 min  at 95 ◦C for the ﬁrst denaturation step, followed by 40 cycles
t  95 ◦C for 20 s and 55 ◦C for 45 s. Each complete ampliﬁcation stage was  fol-
owed by dissociation stage; at 95 ◦C for 15 s, 60 ◦C for 1 min  and 95 ◦C for 15 s.
he 2−CT method of relative quantiﬁcation was used to determine the fold change
n  expression. This was  done by normalizing the resulting threshold cycle (CT) val-
es of the target mRNAs to the CT values of the internal control (-actin) in the
reated and untreated samples (CT = CTtarget − CT-actin) (Schmittgen and Livak,
008).
.7. Measurement of lipid peroxidation
MDA  reacts with TBA as a thiobarbituric acid reactive substance (TBARS) to
roduce a red complex that has a peak absorbance at 535 nm (Janero, 1990). Hip-
ocampi were homogenized with cold 1.5% KCl to make a 10% homogenate. To
.0  ml of the brain homogenate, 2.0 ml  of TCA–TBA–HCl was added and mixed thor-
ughly. The solution was heated for 60 min  in a boiling water bath. After cooling,
he ﬂocculent precipitate was removed by centrifugation at 1000 × g for 10 min.
he  absorbance was determined at 535 nm against a blank that contained all the
eagents except the sample. The amount of MDA  equivalents formed was calculated
sing a molar extinction coefﬁcient of 1.56 × 105 mol−1 cm−1 and expressed as nmol
DA  equivalents/mg protein.
.8. Measurement of total SH groups
Total SH groups were measured using DTNB. This reagent reacts with the
H groups to produce a yellow complex that has a peak absorbance at 412 nm
Ellman, 1959). Brieﬂy, 1 ml  Tris–EDTA buffer (pH = 8.6) was added to 50 l hip-
ocampal homogenate in 2-ml cuvettes and sample absorbance was  read at 412 nm
gainst Tris–EDTA buffer alone (A1). Next, 20 l of DTNB (10 mM in methanol)
as  added to the mixture, and after 15 min  (stored at laboratory tempera-
ure), the sample absorbance was read again (A2). The absorbance of the DTNB
eagent was  read as a blank (B) (Hosseinzadeh et al., 2012). Total thiol concen-
ration (mM)  was calculated from the following equation: total thiol concentration
mM)  = (A2 − A1 − B) × (1.07/0.05) × 13.6..9. Data analysis
Data were expressed as mean ± standard error of the mean (S.E.M.) using SPSS
version 20). Data from behavioral studies, oxidative stress and gene expression
ere analyzed using independent-sample T-tests with a conﬁdence level of 95%.
he  normality distribution of samples with the Kolmogorov–Smirnov test was  done
P  > 0.05). P < 0.05 was considered to be statistically signiﬁcant.-amyloid-injected rats. After 3 weeks of administration of A and treatment of
animals with saline and rutin (100 mg/kg), acquisition and retention tests were per-
formed to evaluate memory performance. Data are mean ± SEM, **P < 0.01 compared
to control group, n = 10.
3. Results
3.1. Effects of rutin on passive avoidance on Aˇ-induced
neurotoxicity
There was  no signiﬁcant difference between the different groups
in the number of trials, thus conﬁrming the uniformity of the
groups. All animals reached the criteria during the training pro-
cedure. In the control and rutin groups, the acquisition trials and
memory retrieval were measured as shown in Fig. 1.
Rutin at a dose of 100 mg/kg signiﬁcantly increased memory
retrieval compared to the control group (t(21) = 2.859, P < 0.01)
(Fig. 1). Also, there were no signiﬁcant differences in the acquisition
trials between the two groups (t(19) = 0.976, P = 0.34).
3.2. Effects of rutin on ERK1, ERK2, CREB and BDNF geneFig. 2. Effects of rutin on CREB, ERK1, ERK2 and BDNF gene expression in the
hippocampi of rats injected with -amyloid. Data are mean ± SEM, *P < 0.05 and
**P  < 0.01, compared to control group, n = 10.
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Fig. 3. Effect of rutin on MDA  levels in the hippocampi of -amyloid-injected rats.


























proinﬂammatory cytokines in SH-SY5Y neuroblastoma cells. It wasig. 4. Effect of rutin on total thiol concentrations in the hippocampus on -
myloid-injected rats. Values are mean ± SEM. ***P < 0.001 compared to control
roup, n = 10.
 = 0.02, t(17) = 2.172, P = 0.04, t(11) = 2.762, P = 0.01) (Fig. 2). How-
ver, ERK2 expression level in the rutin group was  not signiﬁcantly
ifferent from that in the control group (t(17) = 1.162, P = 0.125)
Fig. 2).
.3. TBARS measurement
Post-treatment with rutin 100 mg/kg signiﬁcantly decreased
ree radical-mediated lipid peroxidation compared to that in the
ontrol group (t(21) = 6.486, P < 0.001) (Fig. 3).
.4. Total SH groups assay
The average content of SH groups in the hippocampi of rats
dministered with 100 mg/kg rutin was signiﬁcantly higher than
hat in the hippocampi of the control group (t(23) = 14.212, P < 0.001)
Fig. 4).
. Discussion
In the present study, we investigated the effects of rutin
gainst neurotoxicity of A in rats. Rutin (100 mg/kg) signiﬁcantly
ncreased memory retrieval compared to the control group. It could
igniﬁcantly increase ERK1, CREB and BDNF gene expression in the
ippocampi of rats compared to that in controls. MDA  levels in the
ippocampi of the rutin group were signiﬁcantly lower than those
n the control group. Furthermore, the content of SH groups in rutin
roup was higher than that in the control.
Sublethal concentration of A selectively down-regulated BDNF
ignaling by inhibiting the activation of the Ras–MAPK/ERK and
I3K/Akt pathways and activation of critical transcription factors,
uch as CREB in cultured cortical neurons (Tong et al., 2004).Letters 224 (2014) 108– 113 111
The oligomers of A could inhibit active ERK and CREB
in primary neurons and reduce the downstream post-synaptic
protein NMDA receptor subunit (Ma  et al., 2007). However, stage-
dependent abnormalities have been shown for ERK in mRNA and
protein expression in AD and AD model (Dineley et al., 2001;
Webster et al., 2006).
The critical role of CREB has established in memory, both
long-term consolidation and indirect regulation of short-term
memory. Agents that enhance the activity of CREB have been
suggested to facilitate memory consolidation through increasing
gene expression that is important for long-term memory (Williams
and Spencer, 2012). Reduced phosphorylation of CREB has been
observed in post-mortem brains of AD patients. It seems that
impaired CREB phosphorylation is involved in AD pathophysio-
logy (Scott Bitner, 2012). It was shown that ﬂavonoids activate
the ERK–CREB pathway and activation of this cascade leads to
increased expression and release of BDNF from the synapse through
enhanced CREB activation (Spencer et al., 2009; Vauzour et al.,
2008). BDNF levels are reduced in AD and this has been shown to
correlate with loss of cognition function (Peng et al., 2005, 2009).
It was also shown that BDNF binds to its pre- and post-synaptic
receptors tropomyosin receptor kinase B (TrkB) and triggers glu-
tamate release and phosphatidyl inositiol 3-kinase/mammalian
target of rapamycin (PI3K/mTOR) signaling and activity-regulated
cytoskeleton-associated protein (Arc) synthesis leading to altered
synaptic plasticity (Spencer, 2008).
As our results, it is possible that rutin as a ﬂavonoid, could acti-
vate the ERK–CREB pathway and activation of this cascade leads to
increased expression and release of BDNF from the synapse through
enhanced CREB activation. Thus, it seems that up-regulation of
ERK1, CREB and BDNF expression by rutin could improve memory
and defend against of A neurotoxicity.
Similar to our study, blueberries that contain anthocyanins and
ﬂavanols, enhanced spatial memory in old rats, which also exhib-
ited increased CREB activity and BDNF (Williams et al., 2008).
Furthermore, apigenin could ameliorate AD-associated learning
and memory impairment via inhibiting oxidative stress, and restor-
ing ERK/CREB/BDNF pathway in cerebral cortex of APP/PS1 mice
(Zhao et al., 2013).
Furthermore, it was reported that rutin increased the viability
of trunk neural crest cells in culture. However, cell differentiation
and proliferation did not change. But, in the presence of mitogen
activated kinase kinase (MEK1/2) inhibitors PD98059 (PD) or phos-
phoinositide 3-kinase (PI3K) inhibitor LY294002 (LY) with rutin,
the cell viability was  inhibited. Thus, it was suggested that the
effects of rutin may  be mediated by the ERK and PI3K pathways
(Nones et al., 2012). Low concentrations of quercetin (<10 M),  an
oral metabolite of rutin, could also activate the MAP kinase path-
way including ERK2, JNK1 and p38 leading to expression of some
survival and defensive genes such as c-Fos, c-Jun, phase II detox-
ifying enzymes, glutathione S-transferase and quinone reductase,
resulting in increased Akt and CREB phosphorylation and activated
survival and protective mechanisms (Spencer et al., 2003).
Rutin showed anti-amyloidogenic effects in vitro by reversibly
binding to the amyloid ﬁbril structure of A oligomer and
monomers. Also, it reduced ROS generation in H2O2-treated APP-
swe  cells (Jiménez-Aliaga et al., 2011). It was suggested that free
catechol moiety of ruin helps that father molecule to be oxidized to
its ortho-quinone and this new compound provides metal chelator
properties (Omololu et al., 2011). In addition, rutin dose depend-
ently inhibited aggregation and cytotoxicity of A, attenuated
oxidative stress and decreased the production of nitric oxide andsuggested that the reduction of ROS production of rutin is related to
the enhancement of superoxide dismutase (SOD), glutathione per-
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n xanthine oxidase which is an important enzyme in the oxidative
njury to tissue (Wang et al., 2012).
It was suggested that A causes neurotoxicity via oxidative
tress and increased lipid peroxidation in hippocampus. Similarly,
t was reported that epicatechin could decrease lipid peroxi-
ation and ROS and result in improved memory skills (Cuevas
t al., 2009). Furthermore, pretreatment with rutin before global
erebral ischemia, improved impairment in short-term memory
nd motor coordination on ischemia–reperfusion-induced cerebral
njury. Also, rutin decreased mitochondrial TBARS (Gupta et al.,
003). Also, rutin supplementation was effective in memory dys-
unction induced by streptozotocin in Morris water maze test. It
as also reduced TBARS, glutathione (GSH) and nitrite level (Javed
t al., 2012).
Rutin has neuroprotective effect in the brain ischemia and
retreatment with rutin reduced TBARS, H2O2 and GSH in the hip-
ocampus and frontal cortex in the middle cerebral artery occlusion
MCAO) in rats. It also ameliorated morphological damage and
ttenuated ischemic neural apoptosis by reducing the expression of
53 and increasing of antioxidant enzymatic activities (Khan et al.,
009).
Thus, it is possible that post-treatment of rutin not only acti-
ated the MAPK pathway but also inhibited oxidative stress and
ncreased antioxidant activity during initiation of neurotoxicity
nduced by A, and then, could reduce memory impairment in
nimals.
In conclusion, our ﬁnding showed a possibility that rutin may
ave beneﬁcial effects against A (1–42)-induced neurotoxicity. It
mproved memory impairment caused by injection of A in rats
hrough activation of MAPK and BDNF. Furthermore, it reduced
xidative stress in the hippocampi of rats by reducing MDA  level
nd increasing thiol content in the hippocampus. Further studies
re necessary to clarify the effects and molecular mechanisms of
his ﬂavonoid.
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